Human OCTN2 (SLC22A5) is down-regulated in virus- and nonvirus-mediated cancer

Cell Biochemistry and Function

Volumn 30, Issue 5, 2012, Pages 419-425

  Scalise, Mariafrancesca ^a   Galluccio, Michele ^a   Accardi, Rosita ^b   Cornet, Iris ^b   Tommasino, Massimo ^b   Indiveri, Cesare ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cancer; Carnitine; OCTN2; Transport; Tumour

Indexed keywords

5 AZA CYTIDINE; CARNITINE; CARRIER PROTEINS AND BINDING PROTEINS; MESSENGER RNA; OCTN2 PROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPITHELIUM CELL; GENETIC TRANSCRIPTION; GENOME; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CARCINOGENESIS;

ANIMALS; DOWN-REGULATION; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; NEOPLASMS; NIH 3T3 CELLS; ORGANIC CATION TRANSPORT PROTEINS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84863333022     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2816     Document Type: Article

References (33)

1. Eraly SA, Monte JC, Nigam SK. Novel slc22 transporter homologs in fly, worm, and human clarify the phylogeny of organic anion and cation transporters. Physiol Genomics 2004; 18: 12-24.
2. Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J 2002; 361: 417-412.
3. Indiveri C, Pochini L, Oppedisano F, Tonazzi A. The carnitine transporter network: interactions with drugs. Curr Chem Biol 2010; 4: 108-123.
4. Tamai I, Ohashi R, Nezu JI, et al. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem 2000; 275: 40064-40072.
5. Pochini L, Oppedisano F, Indiveri C. Reconstitution into liposomes and functional characterization of the carnitine transporter from renal cell plasma membrane. Biochim Biophys Acta 2004; 1661: 78-86.
6. Pochini L, Scalise M, Indiveri C. Inactivation by omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes. Chem Biol Interact 2009; 179: 394-401.
7. Ohashi R, Tamai I, Nezu JI, et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 2001; 59: 358-366.
8. Koepsell H, Lips K, Volk C. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications. Pharm Res 2007; 7: 1227-1251.
9. Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, Aleisa AM, Al-Rejaie SS. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol 2010; 640: 143-149.
10. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999; 21: 91-94.
11. Wang Y, Ye J, Ganapathy V, Longo N. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Nat Acad Sci USA 1999; 96: 2356-2360.
12. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004; 36: 471-475.
13. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-530.
14. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009; 121: 29-40.
15. Prip-Buus C, Bouthillier-Voisin AC, Kohl C, Demaugre F, Girard J, Pegorier JP. Evidence for an impaired long-chain fatty acid oxidation and ketogenesis in Fao hepatoma cells. Eur J Biochem 1992; 209: 291-298.
16. Indiveri C, Tonazzi A, Palmieri F. The reconstituted carnitine carrier from rat liver mitochondria: evidence for a transport mechanism different from that of the other mitochondrial translocators. Biochim Biophys Acta 1994; 1189: 65-73.
17. D'Argenio G, Calvani M, Casamassimi A, et al. Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes. FASEB J 2006; 20: 2544-2546.
18. Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol 2000; 182: 339-350.
19. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
20. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24: 11-25.
21. Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 2009; 384: 285-293.
22. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
23. Caldeira S, Zehbe I, Accardi R, et al. The E6 and E7 proteins of cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003; 77: 2195-2206.
24. Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, Mattingly RF. Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. Science 1977; 196: 1456-1458.
25. Au Yeung CL, Tsang WP, Co NN, Yau PL, Kwok TT. HPV-16 E6 upregulation of DNMT1 trough repression of tumor suppressor p53. Oncol Rep 2010; 24: 1599-1604.
26. Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Canc Res 2001; 7: 1982-1986.
27. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010; 40: 1-13.
28. van Vlies N, Ferdinandusse S, Turkenburg M, Wanders RJ, Vaz FM. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim Biophys Acta 2007; 1767: 1134-1142.
29. Luci S, Geissler S, Konig B, et al. PPARalpha agonists up-regulate organic cation transporters in rat liver cells. Biochem Biophys Res Commun 2006; 350: 704-708.
30. D'Argenio G, Petillo O, Margarucci S, et al. Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis. J Biol Chem 2010; 285: 27078-27087.
31. Dai Y, Wang WH. Peroxisome proliferator-activated receptor γ and colorectal cancer. World J Gastrointest Oncol 2010; 15: 159-164.
32. Idell-Wenger JA, Grotyohann LW, Neely JR. Coenzyme A and carnitine distribution in normal and ischemic hearts. J Biol Chem 1978; 253: 4310-4318.
33. Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, Aleisa AM, Al-Rejaie SS. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol 2010; 640: 143-149.